Developmental Therapeutics Core

Director: Andrew Mazar, Ph.D.
Assistant Director: Irawati Kandela, Ph.D.

Location: Silverman Hall B715

Overview:

The Developmental Therapeutics Core (DTC), under the umbrella of the Center of the Developmental Therapeutics (CDT), provides services focused on supporting the translation of new therapeutics to the clinic. The Core supports investigators interested in advancing new compounds into clinical trials including drug assessment and clinical protocol support. In addition, the DTC will interact with universities and companies in teh community that are intersted in utilizing the DTC expertise to herp advance their translational projects.

The Core offers a full suite of fee-for-service tumor biology and translational support services including:

  • in vitro and in vivo assessment of drug activity and mechanism of action
  • exploratory drug development activities such as pharmacokinetics and toxicology
  • consultation and project management
  • clinical trial support

The DTC staff have extensive expertise in animal disease models, drug development and assessment, and clinical translation.

The DTC is a Core of the Robert H. Lurie Comprehensive Cancer Center (RHLCCC), an NCI designated comprehensive cancer center that oversees robust basic science and clinical research programs in the fields of cancer mechanism, therapeutics, diagnostics, and cancer prevention, and resides within the Chemistry of Life Processes Institute.

Tumor Biology Core